Your browser doesn't support javascript.
loading
CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency.
Bidinosti, Michael; Botta, Paolo; Krüttner, Sebastian; Proenca, Catia C; Stoehr, Natacha; Bernhard, Mario; Fruh, Isabelle; Mueller, Matthias; Bonenfant, Debora; Voshol, Hans; Carbone, Walter; Neal, Sarah J; McTighe, Stephanie M; Roma, Guglielmo; Dolmetsch, Ricardo E; Porter, Jeffrey A; Caroni, Pico; Bouwmeester, Tewis; Lüthi, Andreas; Galimberti, Ivan.
Afiliación
  • Bidinosti M; Developmental Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Botta P; Friedrich Miescher Institute, Basel, Switzerland.
  • Krüttner S; Friedrich Miescher Institute, Basel, Switzerland.
  • Proenca CC; Developmental Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Stoehr N; Developmental Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Bernhard M; Developmental Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Fruh I; Developmental Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Mueller M; Developmental Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Bonenfant D; Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Voshol H; Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Carbone W; Developmental Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Neal SJ; Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, USA.
  • McTighe SM; Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, USA.
  • Roma G; Developmental Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Dolmetsch RE; Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, USA.
  • Porter JA; Developmental Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Caroni P; Friedrich Miescher Institute, Basel, Switzerland.
  • Bouwmeester T; Developmental Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Lüthi A; Friedrich Miescher Institute, Basel, Switzerland.
  • Galimberti I; Developmental Molecular Pathways, Novartis Institutes for Biomedical Research, Basel, Switzerland. ivan.galimberti@novartis.com.
Science ; 351(6278): 1199-203, 2016 Mar 11.
Article en En | MEDLINE | ID: mdl-26847545
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas Tirosina Quinasas / Proteínas Serina-Treonina Quinasas / Trastorno del Espectro Autista / Proteínas del Tejido Nervioso Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Science Año: 2016 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas Tirosina Quinasas / Proteínas Serina-Treonina Quinasas / Trastorno del Espectro Autista / Proteínas del Tejido Nervioso Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Science Año: 2016 Tipo del documento: Article País de afiliación: Suiza